Bli medlem
Bli medlem

Du är här


Moberg Pharma: Change in number of shares and votes in Moberg Pharma

STOCKHOLM, December 30, 2015. The number of shares and votes in Moberg
Pharma AB (publ) has increased by 215,985 to 14,217,522 during
December 2015. Therefore, there are in total 14,217,522 shares and
votes in the company as of July 31, 2015.

The reason for the increase is that warrants in Moberg Pharma have
been exercised under the company's share-based incentive program.

For additional information contact:
Peter Wolpert, CEO, Telephone: +46 (0)70 - 735 7135, E-mail:

Anna Ljung, CFO, Telephone: +46 (0)70 - 766 60 30, E-mail:

About this information
Moberg Pharma discloses this information pursuant to the Swedish
Securities Markets Act and/or the Financial Instruments Trading Act.
The information was submitted for publication at 8.30 a.m. (CET) on
December 30, 2015.

About Moberg Pharma,
Moberg Pharma AB (publ) is a rapidly growing Swedish pharmaceutical
company with OTC sales operations in the U.S. and a distributor
network in more than 40 countries. The company's portfolio includes
the OTC brands Kerasal®, Kerasal Nail®, Balmex®, Domeboro®,
Jointflex®, Vanquish®, and Fergon®. Kerasal Nail®(Emtrix®or Nalox™ in
certain markets) is a leading OTC treatment of nail disorders in the
U.S., Canada and several EU markets and is currently being launched
in Southeast Asia. The company is growing organically as well as
through acquisitions. Internal development programs focus on
innovative drug delivery of proven compounds and include two clinical
stage assets, MOB-015 (onychomycosis) and BUPI (pain management in
oral mucositis). Moberg Pharma has offices in Stockholm and New
Jersey and the company's shares are listed on the Small Cap list of
the NASDAQ OMX Nordic Exchange Stockholm (OMX: MOB).


Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.